Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma
Dr. Balar highlights promising evidence on the potential benefits of the use of immunotherapy in the advanced bladder cancer setting.
First-Line Atezolizumab Effective in Cisplatin-Ineligible Urothelial Cancer
Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.
2 Commerce Drive Cranbury, NJ 08512